T2 Biosystems (NASDAQ:TTOO) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of T2 Biosystems (NASDAQ:TTOO) in a report released on Friday. The firm issued a sell rating on the medical equipment provider’s stock.

T2 Biosystems Price Performance

TTOO stock opened at $0.35 on Friday. The firm has a 50 day moving average of $0.73 and a two-hundred day moving average of $2.78. T2 Biosystems has a 12 month low of $0.31 and a 12 month high of $8.38.

Hedge Funds Weigh In On T2 Biosystems

An institutional investor recently bought a new position in T2 Biosystems stock. Armistice Capital LLC acquired a new position in T2 Biosystems, Inc. (NASDAQ:TTOO) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,658,000 shares of the medical equipment provider’s stock, valued at approximately $8,854,000. Armistice Capital LLC owned about 9.49% of T2 Biosystems at the end of the most recent quarter. 23.18% of the stock is currently owned by institutional investors.

T2 Biosystems Company Profile

T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.